uniQure N.V. (GB:0EE0)
UK Market

uniQure Stock Analysis & Ratings

GB:0EE0 Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$13.8
Average Volume (3M)155.00
Market Cap$643.74M
P/E RatioN/A
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score2
EPS (TTM)0.00



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was uniQure’s price range in the past 12 months?
uniQure lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is uniQure’s market cap?
    uniQure’s market cap is $643.74M.
      What is uniQure’s price target?
      The average price target for uniQure is $53.57. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $90.00 ,the lowest forecast is $37.00. The average price target represents 288.19% Increase from the current price of $13.8.
        What do analysts say about uniQure?
        uniQure’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
          When is uniQure’s upcoming earnings report date?
          uniQure’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
            How were uniQure’s earnings last quarter?
            uniQure released its earnings results on May 02, 2022. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of -$0.932 by -$0.068.
              Is uniQure overvalued?
              According to Wall Street analysts uniQure’s price is currently Undervalued.
                Does uniQure pay dividends?
                uniQure does not currently pay dividends.
                What is uniQure’s EPS estimate?
                uniQure’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does uniQure have?
                uniQure has 46,650,000 shares outstanding.
                  What happened to uniQure’s price movement after its last earnings report?
                  uniQure reported an EPS of -$1 in its last earnings report, missing expectations of -$0.932. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of uniQure?
                    Among the largest hedge funds holding uniQure’s share is Carlson Capital LP. It holds uniQure’s shares valued at 1M.


                      uniQure Stock Analysis

                      Smart Score
                      Price Target
                      ▲(288.19% Upside)
                      Strong Buy
                      The uniQure stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      uniQure N.V.

                      uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

                      Similar Stocks
                      Price & Change
                      Sangamo Biosciences
                      Sanofi-Aventis Sa
                      Bristol Myers

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis